Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Physical activity levels are low in patients with pulmonary hypertension.

González-Saiz L, Santos-Lozano A, Fiuza-Luces C, Sanz-Ayán P, Quezada-Loaiza CA, Ruiz-Casado A, Alejo LB, Flox-Camacho A, Morán M, Lucia A, Escribano-Subías P.

Ann Transl Med. 2018 Jun;6(11):205. doi: 10.21037/atm.2018.05.37.

2.

Lung Transplantation in Pulmonary Hypertension: A Multidisciplinary Unit's Management Experience.

Quezada-Loaiza CA, de Pablo Gafas A, Pérez V, Alonso R, Juarros L, Real MI, López E, Cortes M, Meneses JC, González IH, Díaz-Hellín Gude V, Subías PE, Gámez P.

Transplant Proc. 2018 Jun;50(5):1496-1503. doi: 10.1016/j.transproceed.2018.02.073. Epub 2018 Mar 9.

PMID:
29880377
3.

Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre.

Quezada Loaiza CA, Velázquez Martín MT, Jiménez López-Guarch C, Ruiz Cano MJ, Navas Tejedor P, Carreira PE, Flox Camacho Á, de Pablo Gafas A, Delgado Jiménez JF, Gómez Sánchez MÁ, Escribano Subías P.

Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):915-923. doi: 10.1016/j.rec.2016.12.044. Epub 2017 Apr 26. English, Spanish.

PMID:
28454887
4.

Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class.

Santos-Lozano A, Sanz-Ayan P, González-Saiz L, Quezada-Loaiza CA, Fiuza-Luces C, Flox-Camacho A, Munguía-Izquierdo D, Santalla A, Morán M, Escribano-Subías P, Lucia A.

Data Brief. 2017 Mar 18;12:37-41. doi: 10.1016/j.dib.2017.03.022. eCollection 2017 Jun.

5.

Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial.

González-Saiz L, Fiuza-Luces C, Sanchis-Gomar F, Santos-Lozano A, Quezada-Loaiza CA, Flox-Camacho A, Munguía-Izquierdo D, Ara I, Santalla A, Morán M, Sanz-Ayan P, Escribano-Subías P, Lucia A.

Int J Cardiol. 2017 Mar 15;231:277-283. doi: 10.1016/j.ijcard.2016.12.026.

PMID:
28189191
6.

The First Experience of Pulmonary Veno-occlusive Disease Treatment With Macitentan and Sildenafil.

Chamorro Fernández CI, Garcés Cabello P, Pérez Mateos R, Sánchez Soriano RM, Ferrando Siscar C, Quezada Loaiza CA.

Rev Esp Cardiol (Engl Ed). 2017 May;70(5):396-397. doi: 10.1016/j.rec.2016.07.011. Epub 2016 Nov 10. English, Spanish. No abstract available.

PMID:
27840150
7.

Rationale and Design of a Randomized Controlled Trial Evaluating Whole Muscle Exercise Training Effects in Outpatients with Pulmonary Arterial Hypertension (WHOLEi+12).

Sanchis-Gomar F, González-Saiz L, Sanz-Ayan P, Fiuza-Luces C, Quezada-Loaiza CA, Flox-Camacho A, Santalla A, Munguía-Izquierdo D, Santos-Lozano A, Pareja-Galeano H, Ara I, Escribano-Subías P, Lucia A.

Cardiovasc Drugs Ther. 2015 Dec;29(6):543-550. doi: 10.1007/s10557-015-6623-4.

PMID:
26521182
8.

Predictive value of NT-proBNP combined with exercise capacity variables in pulmonary artery disease: Insights from a Spanish cohort.

Quezada-Loaiza CA, Flox-Camacho A, Santos-Lozano A, Sanchis-Gomar F, González-Saiz L, Sanz-Ayan P, Garatachea N, Lucia A, Escribano-Subías P.

Int J Cardiol. 2015;186:32-4. doi: 10.1016/j.ijcard.2015.03.155. Epub 2015 Mar 17. No abstract available.

PMID:
25804462
9.

Impact of the Xpert(®) MTB/RIF molecular test on the late diagnosis of pulmonary tuberculosis.

Ramirez HL, García-Clemente MM, Alvarez-Álvarez C, Palacio-Gutierrez JJ, Pando-Sandoval A, Gagatek S, Arias-Guillén M, Quezada-Loaiza CA, Casan-Clará P.

Int J Tuberc Lung Dis. 2014 Apr;18(4):435-7. doi: 10.5588/ijtld.13.0747.

PMID:
24670698

Supplemental Content

Loading ...
Support Center